Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation Point of Care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced that is has closed private financing for approximately $12 million.
The financing, received from a strategic corporate partner and existing investors, will fund the completion of development, registration clinical trials, and commercial launch of the Company's mobile diagnostic platform and initial assays.
New research highlights regional variations in COPD prevalence according to diagnostic criteria